>
BridgeBio Pharma Inc logo

BBIO - BridgeBio Pharma Inc Share Price

$53.66 2.9  5.8%

Last Trade - 14/05/21

Sector
Healthcare
Size
Large Cap
Market Cap £5.68bn
Enterprise Value £6.01bn
Revenue £6.18m
Position in Universe 1068th / 6846
Bullish
Bearish
Unlock BBIO Revenue
Momentum
Relative Strength (%)
1m -2.39%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -27.0%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 0.000 40.6 8.25 76.3 106.6
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the three months ended 31 March 2021, BridgeBioPharma Inc revenues increased from $0K to $462K. Net lossincreased 78% to $163.1M. Revenues reflect an increase indemand for the Company's products and services due tofavorable market conditions. Higher net loss reflectsResearch and development increase of 50% to $100.1M(expense), Stock-Based Compensation increase from $1.6M to$22.4M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

BBIO Revenue Unlock BBIO Revenue

Net Income

BBIO Net Income Unlock BBIO Revenue

Normalised EPS

BBIO Normalised EPS Unlock BBIO Revenue

PE Ratio Range

BBIO PE Ratio Range Unlock BBIO Revenue

Dividend Yield Range

BBIO Dividend Yield Range Unlock BBIO Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
BBIO EPS Forecasts Unlock BBIO Revenue
Profile Summary

BridgeBio Pharma, Inc. is discovering and developing medicines that target well-characterized genetic diseases. The Company’s product platform divided into three key categories: Mendelian, Oncology and Gene therapy. The Company’s pipeline programs include product candidates ranging from early discovery to late-stage development. The Company’s products include BBP-265, BBP-831, BBP-631 and BBP-454.

Directors
Last Annual December 31st, 2020
Last Interim March 31st, 2021
Incorporated May 17, 2019
Public Since June 27, 2019
No. of Shareholders: 35
No. of Employees: 385
Sector Healthcare
Industry Pharmaceuticals
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 149,284,184
Free Float (0.0%)
Eligible for
ISAs
SIPPs
BBIO Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for BBIO
Upcoming Events for BBIO
Wednesday 2nd June, 2021 Estimate
BridgeBio Pharma Inc Annual Shareholders Meeting
Thursday 17th June, 2021
BridgeBio Pharma Inc Annual Shareholders Meeting
Monday 9th August, 2021 Estimate
Q2 2021 BridgeBio Pharma Inc Earnings Release
Wednesday 3rd November, 2021 Estimate
Q3 2021 BridgeBio Pharma Inc Earnings Release
Frequently Asked Questions for BridgeBio Pharma Inc
What is the BridgeBio Pharma Inc share price?

As of 14/05/21, shares in BridgeBio Pharma Inc are trading at $53.66, giving the company a market capitalisation of £5.68bn. This share price information is delayed by 15 minutes.

How has the BridgeBio Pharma Inc share price performed this year?

Shares in BridgeBio Pharma Inc are currently trading at $53.66 and the price has moved by 75.36% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the BridgeBio Pharma Inc price has moved by 22.11% over the past year.

What are the analyst and broker recommendations for BridgeBio Pharma Inc?

There are no analysts currently covering BridgeBio Pharma Inc.

When will BridgeBio Pharma Inc next release its financial results?

BridgeBio Pharma Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2022-03-31
What is the BridgeBio Pharma Inc dividend yield?

BridgeBio Pharma Inc does not currently pay a dividend.

Does BridgeBio Pharma Inc pay a dividend?

BridgeBio Pharma Inc does not currently pay a dividend.

When does BridgeBio Pharma Inc next pay dividends?

BridgeBio Pharma Inc does not currently pay a dividend.

How do I buy BridgeBio Pharma Inc shares?

To buy shares in BridgeBio Pharma Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of BridgeBio Pharma Inc?

Shares in BridgeBio Pharma Inc are currently trading at $53.66, giving the company a market capitalisation of £5.68bn.

Where are BridgeBio Pharma Inc shares listed? Where are BridgeBio Pharma Inc shares listed?

Here are the trading details for BridgeBio Pharma Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: BBIO
What kind of share is BridgeBio Pharma Inc?

Based on an overall assessment of its quality, value and momentum, BridgeBio Pharma Inc is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a BridgeBio Pharma Inc share price forecast 2021?

Shares in BridgeBio Pharma Inc are currently priced at $53.66. At that level they are trading at 52.12% discount to the analyst consensus target price of 0.00.

Analysts covering BridgeBio Pharma Inc currently have a consensus Earnings Per Share (EPS) forecast of -3.815 for the next financial year.

How can I tell whether the BridgeBio Pharma Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BridgeBio Pharma Inc. Over the past six months, the relative strength of its shares against the market has been 8.74%. At the current price of $53.66, shares in BridgeBio Pharma Inc are trading at 5.61% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the BridgeBio Pharma Inc PE Ratio?

We were not able to find PE ratio data for BridgeBio Pharma Inc.

Who are the key directors of BridgeBio Pharma Inc?

BridgeBio Pharma Inc's management team is headed by:

Neil Kumar - CEO
Brian Stephenson - CFO
Uma Sinha - CSO
Charles Homcy - CEX
Frank Mccormick - CEX
Richard Scheller - CEX
Michael Henderson - OTH
Cameron Turtle - SVP
Eric Aguiar - IND
James Momtazee - IND
Ronald Daniels - IND
Jennifer Cook - IND
Andrew Lo - IND
Who are the major shareholders of BridgeBio Pharma Inc?

Here are the top five shareholders of BridgeBio Pharma Inc based on the size of their shareholding:

Kohlberg Kravis Roberts & Co. L.P. Private Equity
Percentage owned: 20.81% (31.1m shares)
Viking Global Investors LP Hedge Fund
Percentage owned: 17.83% (26.6m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 6.26% (9.34m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 4.92% (7.34m shares)
Perceptive Advisors LLC Private Equity
Percentage owned: 4.49% (6.71m shares)
Similar to BBIO
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.